Pediatric acute myeloid leukemia
Conditions
Interventions
Experimental group:P-AML-2025 regimen
Sponsors
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1) <18 years old; 2) Patients diagnosed with non-M3-AML according to the revised WHO criteria in 2022; 3) had not received any systemic treatment for AML before enrollment in this study; 4) Children can swallow tablets. 5) Sign informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1) Acute promyelocytic leukemia, acute myeloid leukemia associated with Down syndrome, acute heterozygotic leukemia; 2) Sudden change of CML;Secondary to MDS/MPN;Treatment-associated AML; 3) Secondary to immune deficiency or congenital bone marrow depletion disease; 4) Patients with any history of chemotherapy or radiotherapy in the previous 3 months (emergency radiotherapy for relieving symptoms of compression is not included).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimal residual disease, MRD;Event-free survival, EFS;Overall survival, OS;Adverse reaction; | — |
Countries
China
Contacts
Public ContactZhu Xiaofan
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
Outcome results
None listed